Introduction

Acute hepatitis B is a newly acquired infection with hepatitis B virus (HBV), characterized by a period of viral replication followed by an immune response that may result in clinical hepatitis and, in most immunocompetent adults, eventual viral clearance.

The clinical spectrum is extremely broad:

asymptomatic infection → mild hepatitis → symptomatic acute hepatitis → severe hepatitis → fulminant acute liver failure

The most important determinant of outcome is the interaction between:

• Age at infection

• Host immune response

• Viral replication

• Viral genotype and variants

• Coinfections

• Underlying liver disease

A central principle is:

1. Definition

Acute HBV infection

Acute HBV infection refers to newly acquired HBV infection during the early phase following exposure.

It is characterized by:

• HBV replication

• HBsAg positivity during most of the detectable acute phase

• Appearance of anti-HBc, particularly IgM anti-HBc

• Variable ALT elevation

• Variable clinical symptoms

• Possible HBeAg positivity

• Eventual clearance or progression to persistent infection

2. Routes of Acquisition

HBV can be transmitted through:

Blood and blood-contaminated exposure

• Transfusion of infected blood/products

• Unsafe injections

• Needle-stick injury

• Sharing contaminated needles

• Unsafe medical procedures

• Tattooing/piercing with contaminated equipment

Sexual transmission

• Unprotected sexual exposure

• Multiple sexual partners

• Sexual contact with an infected person

Perinatal transmission

Transmission from an infected mother to the infant around the time of birth is particularly important because infection acquired early in life has a high probability of becoming chronic.

Household exposure

Particularly through exposure to infected blood/body fluids and in settings where close contact with blood-contaminated personal items occurs.

3. Entry and Initial Infection

After exposure, HBV reaches the bloodstream.

The virus eventually reaches hepatocytes.

The viral large surface protein interacts with:

NTCP

on hepatocytes.

This facilitates viral entry.

The nucleocapsid then reaches the nucleus where:

rcDNA → cccDNA

The newly formed cccDNA acts as the template for viral transcription.

4. Incubation Period

The incubation period of acute HBV is relatively long.

Typically:

Approximately 60–150 days

with an average of around:

90 days

The exact duration varies depending on:

• inoculum

• route of transmission

• viral load

• host immune response

• timing of detectable viremia

5. What Happens During the Incubation Period?

During the early phase:

HBV exposure
      ↓
Hepatocyte infection
      ↓
cccDNA formation
      ↓
Viral replication
      ↓
HBV DNA increases
      ↓
HBsAg becomes detectable
      ↓
HBeAg may appear
      ↓
Immune response develops
      ↓
ALT rises
      ↓
Clinical symptoms may appear

Importantly:

Viral replication precedes many clinical manifestations.

6. Early Virological Phase

HBV DNA can become detectable before:

• symptoms

• jaundice

• ALT elevation

• anti-HBc seroconversion

HBsAg generally becomes detectable during this early period.

HBeAg may also be present, particularly when viral replication is high.

7. HBV DNA During Acute Infection

HBV DNA is a direct marker of viral replication.

It can become detectable early after infection.

During the initial phase:

HBV DNA rises

↓

viral antigen production increases

↓

host immune response intensifies

↓

HBV DNA begins to fall

Therefore, declining HBV DNA can accompany effective immune control.

8. HBsAg in Acute Infection

HBsAg is usually the first routinely detected serological marker of HBV infection.

It can become positive before:

• clinical symptoms

• jaundice

• ALT elevation

• anti-HBc IgM

If the patient clears HBV:

HBsAg disappears

followed eventually by:

anti-HBs appearance

9. HBeAg in Acute Infection

HBeAg is often detectable during the early replicative phase.

Its presence generally correlates with:

• active viral replication

• high HBV DNA

• increased infectiousness

However:

And some acute infections may be:

HBeAg negative

particularly when infecting viral variants do not produce normal amounts of HBeAg.

10. Development of Anti-HBc IgM

The appearance of:

IgM anti-HBc

is one of the most important markers of acute/recent HBV infection.

Typical pattern:

HBsAg +

IgM anti-HBc +

anti-HBs −

This strongly supports acute infection.

11. Total Anti-HBc

Total anti-HBc includes predominantly:

• IgM

• IgG

During acute infection:

total anti-HBc becomes positive

and remains detectable long after the acute infection resolves.

Therefore:

IgM anti-HBc = recent infection

while:

IgG/total anti-HBc = current or previous natural infection

12. Acute HBV Serological Evolution

A simplified sequence:

Exposure
   ↓
HBV DNA
   ↓
HBsAg
   ↓
HBeAg
   ↓
IgM anti-HBc
   ↓
ALT elevation
   ↓
Clinical hepatitis
   ↓
HBeAg disappearance
   ↓
Anti-HBe
   ↓
HBsAg disappearance
   ↓
Anti-HBs

The exact timing varies between patients.

13. Prodromal Phase

Symptomatic acute hepatitis B may begin with a prodromal or pre-icteric phase.

Symptoms can include:

• Fatigue

• Malaise

• Anorexia

• Nausea

• Vomiting

• Low-grade fever

• Headache

• Myalgia

• Arthralgia

• Right upper quadrant discomfort

Some patients develop a serum sickness-like syndrome.

14. Serum Sickness-Like Prodrome

A classic pre-icteric manifestation can include:

• fever

• skin rash

• arthralgia

• myalgia

This is thought to relate partly to circulating immune complexes.

It may occur before overt jaundice.

15. Icteric Phase

When clinical hepatitis develops, patients may develop:

• jaundice

• dark urine

• pale stools

• nausea

• anorexia

• fatigue

• right upper quadrant discomfort

• hepatomegaly

The degree of jaundice varies substantially.

Many infections remain asymptomatic.

16. Laboratory Features

Typical laboratory findings include:

Aminotransferases

• ALT elevated

• AST elevated

ALT often rises substantially.

Bilirubin

May increase, particularly in icteric disease.

Alkaline phosphatase

May be normal or moderately elevated.

Prothrombin time/INR

Important for assessing severe hepatic dysfunction.

17. ALT Elevation

ALT reflects:

Hepatocellular injury

In acute hepatitis B:

immune response

↓

infected hepatocyte injury

↓

intracellular enzyme release

↓

ALT elevation

Therefore:

18. Relationship Between Viral Load and ALT

An important conceptual point is:

High HBV DNA does not necessarily mean maximal liver injury.

In the early phase:

HBV DNA may be very high

while:

ALT may still be normal.

Later:

HBV-specific immune response increases

↓

ALT rises

↓

HBV DNA may fall.

Thus, the relationship between HBV DNA and ALT is dynamic.

19. Histopathology

Liver biopsy is not routinely required for diagnosing uncomplicated acute HBV infection.

When examined histologically, findings may include:

• Lobular inflammation

• Portal inflammation

• Hepatocyte degeneration

• Hepatocyte apoptosis/necrosis

• Kupffer-cell activation

• Variable cholestasis

The severity depends on the intensity of immune-mediated injury.

20. Immunopathogenesis of Acute Hepatitis B

The key sequence is:

HBV infection
     ↓
HBV antigen presentation
     ↓
CD4+ T-cell activation
     ↓
CD8+ CTL activation
     ↓
Recognition of HBV-infected hepatocytes
     ↓
Perforin/granzyme + Fas/FasL
     ↓
Hepatocyte apoptosis/death
     ↓
ALT/AST elevation
     ↓
Clinical hepatitis

At the same time:

IFN-γ + TNF-α

can suppress viral replication through non-cytolytic mechanisms.

21. Why Some Patients Are Asymptomatic

Many acute HBV infections produce few or no symptoms.

This can occur because:

• immune-mediated injury is limited

• the infection is controlled without extensive hepatocyte destruction

• the patient does not develop clinically significant jaundice

• symptoms are nonspecific and may go unnoticed

Therefore:

22. Acute Hepatitis B in Adults

Immunocompetent adults generally mount a relatively strong HBV-specific immune response.

This produces:

viral suppression

and often:

HBsAg clearance + anti-HBs development

Therefore, most immunocompetent adults with newly acquired HBV infection do not progress to chronic infection.

23. Age and Risk of Chronicity

The most important determinant of progression to chronic infection is:

Age at acquisition

The younger the age at infection, the greater the likelihood of chronic persistence.

Approximate conceptual relationship

Perinatal/infancy infection

→ very high chronicity risk

Early childhood infection

→ substantial chronicity risk

Adult infection

→ much lower chronicity risk in immunocompetent individuals

The exact percentages vary among populations and clinical circumstances.

24. Why Infants Are More Likely to Develop Chronic Infection

The mechanisms are complex but include:

• immature immune responses

• altered HBV-specific T-cell responses

• high antigen exposure

• maternal HBeAg-associated immune modulation

• reduced effective immune-mediated clearance

Thus:

In fact, silent infection may progress to lifelong chronic HBV infection.

25. Outcome of Acute HBV Infection

There are three major outcomes:

1. Complete recovery

HBsAg disappears and anti-HBs develops.

2. Chronic infection

HBsAg persists ≥6 months.

3. Fulminant hepatitis

Rare but potentially fatal acute liver failure.

26. Recovery From Acute HBV

Successful clearance typically involves:

HBV DNA decline

↓

HBeAg disappearance

↓

anti-HBe appearance

↓

HBsAg disappearance

↓

anti-HBs appearance

↓

long-term immune control

Total anti-HBc/IgG generally persists.

27. Resolved Acute HBV Infection

Typical post-recovery profile:

This represents:

Resolved natural HBV infection

28. The Window Period

During recovery:

HBsAg disappears

before:

anti-HBs becomes detectable

This produces the:

HBV window period

Typical pattern:

• HBsAg −

• anti-HBs −

• IgM anti-HBc +

• total anti-HBc +

Most important diagnostic marker

IgM anti-HBc

29. Chronicity After Acute Infection

If the immune system fails to eliminate HBV:

HBsAg persists

↓

HBV DNA may persist

↓

cccDNA remains in hepatocytes

↓

chronic HBV infection

The risk is strongly age dependent.

30. Severe Acute Hepatitis

A minority of patients develop severe acute hepatitis.

Features may include:

• marked jaundice

• coagulopathy

• very high aminotransferases

• hepatic dysfunction

• encephalopathy

This requires urgent medical evaluation.

31. Fulminant Hepatitis B

Fulminant hepatitis B is characterized by:

Acute liver injury

plus

impaired hepatic synthetic function

plus

hepatic encephalopathy

in the appropriate clinical setting.

It can progress rapidly to:

• cerebral edema

• coagulopathy

• renal dysfunction

• multiorgan failure

• death

32. Pathogenesis of Fulminant Hepatitis

The precise mechanism is complex.

An intense immune response against infected hepatocytes is considered an important contributor.

Possible mechanisms include:

• massive CTL-mediated injury

• widespread hepatocyte apoptosis/necrosis

• cytokine-mediated injury

• microcirculatory disturbances

• mitochondrial dysfunction

The result is:

massive hepatocyte loss

↓

acute liver failure

33. HBV Coinfection and Severe Disease

Severe hepatitis may occur in the setting of:

• HBV + HDV coinfection

• HDV superinfection in an HBV carrier

• other viral/chemical insults

• underlying liver disease

HDV is particularly important because it can markedly increase the severity of acute hepatitis.

34. Extrahepatic Manifestations During Acute Infection

Acute HBV infection can produce manifestations outside the liver.

These may include:

• arthralgia

• arthritis

• rash

• serum sickness-like syndrome

• vasculitis

• renal manifestations

These are largely related to immune mechanisms and circulating immune complexes.

35. Diagnosis of Acute HBV Infection

The most useful combination is:

HBsAg

plus

IgM anti-HBc

A typical acute infection profile:

HBsAg +

IgM anti-HBc +

anti-HBs −

with variable:

• HBeAg

• HBV DNA

• ALT

36. Role of HBV DNA in Acute Infection

HBV DNA is useful when:

• serology is ambiguous

• early infection is suspected

• immunosuppression complicates interpretation

• occult infection is considered

• monitoring is clinically indicated

It is especially useful as a direct molecular measure of viral replication.

37. Differential Diagnosis of Acute Viral Hepatitis

Acute hepatitis with jaundice may be caused by:

• HAV

• HBV

• HCV

• HDV

• HEV

• EBV

• CMV

• HSV in selected severe cases

Therefore, HBV serology should be interpreted within a broader acute hepatitis workup when clinically indicated.

38. Acute HBV vs Acute HCV

39. Acute HBV vs Chronic HBV

40. Treatment of Acute Hepatitis B

For most uncomplicated acute HBV infections:

Supportive management is sufficient.

Management generally includes:

• hydration

• adequate nutrition

• symptom control

• avoidance of hepatotoxic medications/substances where appropriate

• monitoring of liver function

• monitoring for signs of acute liver failure

Routine antiviral therapy is not required for most uncomplicated acute HBV infections.

41. When Antiviral Therapy May Be Considered

Antiviral therapy may be considered in:

• severe acute hepatitis

• prolonged/severe disease

• acute liver failure

• selected patients with severe coagulopathy or significant hepatic dysfunction

Specialist hepatology/infectious disease input is appropriate.

Nucleos(t)ide analogues such as:

• tenofovir

• entecavir

may be used in appropriate severe cases.

42. Why Routine Antivirals Are Usually Unnecessary

Most immunocompetent adults with acute HBV infection will spontaneously control the infection.

The immune system is capable of:

• suppressing replication

• eliminating infected hepatocytes

• producing anti-HBs

• establishing long-term immune control

Therefore, routine antiviral treatment of uncomplicated acute HBV is generally unnecessary.

43. Monitoring During Acute HBV

Important parameters include:

Clinical

• jaundice

• mental status

• vomiting

• bleeding

• abdominal pain

• hydration

Biochemical

• ALT

• AST

• bilirubin

• albumin

• PT/INR

• creatinine

Virological

• HBsAg

• anti-HBc IgM

• HBV DNA where indicated

44. Red Flags for Acute Liver Failure

Urgent assessment is required if a patient develops:

• altered mental status

• confusion

• encephalopathy

• significant coagulopathy

• rapidly worsening jaundice

• severe vomiting

• hypoglycemia

• renal dysfunction

• bleeding

• rapidly deteriorating clinical condition

Acute liver failure requires specialist management and consideration of liver transplantation.

45. Infectivity During Acute HBV

Patients can be infectious before the onset of symptoms.

This is because:

HBV DNA and HBsAg become detectable before clinical hepatitis.

Therefore, transmission can occur during the asymptomatic incubation phase.

Infectivity is particularly high when:

• HBV DNA is high

• HBeAg is positive

46. Prevention After Exposure

Acute HBV infection has important public-health implications.

Following significant exposure, post-exposure management may include:

Hepatitis B vaccine

and, in appropriate situations:

Hepatitis B immune globulin (HBIG)

The decision depends on:

• source HBsAg status

• exposed person's vaccination status

• documented immunity

• type of exposure

• timing since exposure

Post-exposure prophylaxis should be initiated as rapidly as possible according to current guidelines.

47. Acute HBV in Pregnancy

Acute HBV infection during pregnancy requires:

• maternal evaluation

• assessment of disease severity

• assessment of HBV DNA

• prevention of perinatal transmission

• neonatal prophylaxis according to guidelines

High maternal HBV DNA increases the risk of perinatal transmission.

48. Acute HBV and Mother-to-Child Transmission

The newborn of an HBsAg-positive mother should receive appropriate neonatal prophylaxis.

This generally includes:

Hepatitis B vaccine

and, when indicated:

HBIG

as soon as possible after birth.

Prevention of perinatal transmission is one of the most effective ways to prevent lifelong chronic HBV infection.

49. Natural History of Acute HBV

Exposure
   ↓
Incubation
   ↓
HBV DNA detectable
   ↓
HBsAg+
   ↓
HBeAg ±
   ↓
Immune activation
   ↓
ALT elevation
   ↓
Prodrome
   ↓
Jaundice ±
   ↓
Viral suppression
   ↓
┌───────────────┴───────────────┐
↓                               ↓
Clearance                     Persistence
↓                               ↓
HBsAg loss                     HBsAg ≥6 months
↓                               ↓
Anti-HBs                        Chronic HBV

Rarely:

Acute HBV
   ↓
Massive immune-mediated
hepatocellular injury
   ↓
Acute liver failure
   ↓
Fulminant hepatitis

50. Complete Serological Evolution

EARLY INFECTION
HBV DNA +
HBsAg +
HBeAg ±
       ↓
IMMUNE RESPONSE
IgM anti-HBc +
ALT ↑
       ↓
RECOVERY
HBeAg ↓
Anti-HBe +
HBV DNA ↓
       ↓
HBsAg disappears
       ↓
WINDOW PERIOD
HBsAg −
Anti-HBs −
IgM anti-HBc +
       ↓
RECOVERY
Anti-HBs +
       ↓
RESOLVED INFECTION
Anti-HBs +
Total anti-HBc +

51. Acute HBV: High-Yield Laboratory Pattern

Classic acute HBV

HBsAg +

IgM anti-HBc +

Total anti-HBc +

anti-HBs −

ALT ↑

HBV DNA +

HBeAg often +

52. The Most Important Distinction

If you remember only one diagnostic rule:

And:

53. High-Yield Exam Pearls

Pearl 1

The incubation period of acute HBV is approximately 2–5 months, commonly around 90 days.

Pearl 2

HBV is predominantly non-cytopathic.

Pearl 3

Much of the liver injury results from the host immune response.

Pearl 4

CD8+ CTLs are central to viral clearance and hepatocellular injury.

Pearl 5

IgM anti-HBc is the key serological marker of acute/recent infection.

Pearl 6

The HBV window period is characterized by:

HBsAg − / anti-HBs − / IgM anti-HBc +

Pearl 7

Acute HBV infection acquired during adulthood is usually cleared in immunocompetent individuals.

Pearl 8

The younger the patient at acquisition, the greater the risk of chronic infection.

Pearl 9

Normal ALT does not exclude early HBV infection.

Pearl 10

HBeAg is associated with high replication/infectivity but is not essential for viral replication.

Pearl 11

HBeAg-negative acute infection can occur.

Pearl 12

Fulminant hepatitis B is rare but potentially fatal.

Pearl 13

Uncomplicated acute HBV generally requires supportive rather than routine antiviral therapy.

Pearl 14

HBV DNA can become detectable before clinical hepatitis.

54. One-Minute Revision

ACUTE HBV

Exposure
   ↓
Incubation ~2–5 months
   ↓
HBV DNA detectable
   ↓
HBsAg+
   ↓
HBeAg ±
   ↓
IgM anti-HBc+
   ↓
ALT ↑
   ↓
Acute hepatitis ± jaundice
   ↓
Immune clearance
   ↓
HBsAg disappears
   ↓
Anti-HBs appears
   ↓
RESOLUTION

If immune clearance fails:

HBV persistence
      ↓
HBsAg ≥6 months
      ↓
CHRONIC HBV

Rarely:

Acute HBV
   ↓
Massive hepatocellular injury
   ↓
Acute liver failure

55. Final Take-Home Message

Acute hepatitis B is fundamentally a dynamic interaction between viral replication and host immunity.

The virus establishes hepatocyte infection and replicates through a cccDNA intermediate. The host immune response then determines whether HBV is eliminated or persists.

A successful immune response produces two apparently opposing outcomes:

viral clearance

and

hepatocellular injury.

The classic diagnostic pattern is:

while:

The most important determinants of long-term outcome are age at infection, immune competence and the effectiveness of HBV-specific immune control.

Standard References

1. Knipe DM, Howley PM, editors. Fields Virology. Wolters Kluwer.

2. Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier.

3. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. Elsevier.

4. Carroll KC, et al. Jawetz, Melnick & Adelberg's Medical Microbiology. McGraw-Hill.

5. Ryan KJ, Ray CG. Sherris Medical Microbiology. McGraw-Hill.

6. World Health Organization. Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection. WHO, 2024.

7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 2025.

8. Terrault NA, et al. AASLD Guidance on Chronic Hepatitis B.

9. Centers for Disease Control and Prevention. Clinical Testing and Diagnosis for Hepatitis B.

10. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. New England Journal of Medicine.

11. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews Immunology.

12. Bertoletti A, Ferrari C. Reviews on HBV-specific T-cell immunity and immune-mediated liver injury.

13. Maini MK, Burton AR. Reviews on HBV-specific immune responses and chronic HBV infection.